SH – CytoSorbents Corporation Related Content
Removal of inflammatory ‘evil humors’ – the key to treating COVID-19 complications?
Phillip P. Chan, MD, PhD, Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO), discusses the use of CytoSorb, a broad-spectrum blood purification technology to treat cytokine storm and hyperinflammation in critically ill COVID-19 patients.
